Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Volenrelaxin
LY3540378 · 1 trial · 1 indication
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3540378 (Part A) | EXPERIMENTAL | Single ascending doses of LY3540378 administered either intravenously (IV) or subcutaneously (SC). |
| LY3540378 (Part B) | EXPERIMENTAL | Multiple ascending doses of LY3540378 administered SC. |
| LY3540378 (Part C) | EXPERIMENTAL | Multiple ascending doses of LY3540378 administered SC in Japanese Participants. |
| LY3540378 (Part D) | EXPERIMENTAL | Multiple ascending doses of LY3540378 administered SC in Chinese Participants. |
| Placebo (Part A, B, C & D) | PLACEBO_COMPARATOR | Placebo administered either IV or SC. |
| Name | Type | Description |
|---|---|---|
| LY3540378 | DRUG | Administered IV or SC. |
| Placebo | DRUG | Administered IV or SC. |
Inclusion Criteria: * Overtly healthy males or females, as determined by medical history and physical examination. * Body mass index (BMI) within the range of 19 to 30 kilograms per meter squared (kg/m²) * For Part C, participants should be first generation Japanese origin. * For Part D, participan...
LY3540378 is an investigational small molecule being developed by Eli Lilly and Company. It has been studied in a Phase 1 clinical trial in healthy participants. The specific disease or condition it is intended to treat has not been disclosed, and it is not approved for any use.
LY3540378 is being developed by Eli Lilly and Company, which trades on the New York Stock Exchange under the ticker LLY. Lilly sponsored the Phase 1 study of the compound in healthy volunteers.
LY3540378 is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA or any other regulatory agency.
LY3540378 has been evaluated in one completed Phase 1 trial, NCT04768855, titled A Study of LY3540378 in Healthy Participants. The trial enrolled 134 healthy volunteers across the United States and Singapore and used a randomized, double-blind, placebo-controlled design.
The Phase 1 trial NCT04768855 was a randomized, double-blind, placebo-controlled study of LY3540378 in healthy participants. It enrolled 134 adults aged 21 and older of any sex in the United States and Singapore. The study has been completed.